| Lee, Kang-Yun |
| Active, not recruiting | 3 | 397 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Placebo | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 04/24 | 04/24 | | |
NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
NCT05243680 / 2020-004334-38: An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) |
|
|
| Recruiting | 3 | 637 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 05/25 | 05/25 | | |
NCT04909034: Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | MS-20, Chemo young, Placebo | Microbio Co Ltd | NSCLC Stage IV | 06/23 | 06/24 | | |
NCT05008965: Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma |
|
|
| Recruiting | 2 | 100 | RoW | FB825, Placebo | Oneness Biotech Co., Ltd., Microbio Shanghai Co., Ltd. | Allergic Asthma | 06/24 | 06/24 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Recruiting | N/A | 500 | RoW | | National Health Research Institutes, Taiwan | Non-small-cell Lung Cancer | 12/25 | 12/30 | | |
| Fu, Pin-Kuei |
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma |
|
|
| Recruiting | 4 | 1136 | Canada, Japan, US, RoW | Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists | GlaxoSmithKline | Asthma | 03/26 | 03/26 | | |
NCT05008965: Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma |
|
|
| Recruiting | 2 | 100 | RoW | FB825, Placebo | Oneness Biotech Co., Ltd., Microbio Shanghai Co., Ltd. | Allergic Asthma | 06/24 | 06/24 | | |
| Recruiting | N/A | 300 | RoW | | Taichung Veterans General Hospital | Sarcopenia, COPD, Asthma, ILD | 10/24 | 09/32 | | |
| Recruiting | N/A | 500 | RoW | Biological Treatment for severe asthma patients, Omalizumab, Mepolizumab, Benralizumab, Dupilzumab, Tezepelumab | Taichung Veterans General Hospital, E-DA Hospital, National Cheng-Kung University Hospital, National Yang Ming Chiao Tung University Hospital, Chang Gung Memorial Hospital | Pulmonary Disease, Asthma | 02/43 | 02/43 | | |
| Recruiting | N/A | 10000 | RoW | | Taichung Veterans General Hospital, Tri-Service General Hospital, E-DA Hospital, Chang Gung Memorial Hospital | Interstitial Lung Disease, Comorbidities and Coexisting Conditions, Pulmonary Arterial Hypertension, Treatment Adherence, Function Impaired Respiratory | 12/33 | 12/35 | | |
NCT05926713: Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease |
|
|
| Recruiting | N/A | 100 | RoW | Sarcojoint®, supervised exercise | Orient Europharma Co., Ltd. | Sarcopenia, COPD, ILD | 10/32 | 10/32 | | |
| Chen, Tzu-Tao |
NCT05018299: Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma |
|
|
| Recruiting | 2 | 40 | RoW | FB704A placebo, FB704A | Oneness Biotech Co., Ltd. | Severe Asthma | 09/25 | 09/25 | | |
NCT04347967: Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS) |
|
|
| Not yet recruiting | 1 | 18 | RoW | UMC119-06 | Meridigen Biotech Co., Ltd. | Acute Respiratory Distress Syndrome | 09/24 | 09/25 | | |
| Li, Avan |
NCT05018299: Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma |
|
|
| Recruiting | 2 | 40 | RoW | FB704A placebo, FB704A | Oneness Biotech Co., Ltd. | Severe Asthma | 09/25 | 09/25 | | |
| Chen, Chia-Hung |
NCT06372496: Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma |
|
|
| Recruiting | 4 | 1136 | Canada, Japan, US, RoW | Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists | GlaxoSmithKline | Asthma | 03/26 | 03/26 | | |
NCT05018299: Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma |
|
|
| Recruiting | 2 | 40 | RoW | FB704A placebo, FB704A | Oneness Biotech Co., Ltd. | Severe Asthma | 09/25 | 09/25 | | |
NCT05008965: Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma |
|
|
| Recruiting | 2 | 100 | RoW | FB825, Placebo | Oneness Biotech Co., Ltd., Microbio Shanghai Co., Ltd. | Allergic Asthma | 06/24 | 06/24 | | |
